130 related articles for article (PubMed ID: 14683659)
1. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
Hoogewerf M; Regez RM; Schouten WE; Weigel HM; Frissen PH; Brinkman K
Lancet; 2003 Dec; 362(9400):1979-80. PubMed ID: 14683659
[TBL] [Abstract][Full Text] [Related]
2. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
3. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
4. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
[TBL] [Abstract][Full Text] [Related]
5. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F
Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814
[TBL] [Abstract][Full Text] [Related]
6. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
[TBL] [Abstract][Full Text] [Related]
7. Failure of combination abacavir + tenofovir + lamivudine (3TC).
AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
[TBL] [Abstract][Full Text] [Related]
9. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Delaunay C; Brun-Vézinet F; Landman R; Collin G; Peytavin G; Trylesinski A; Flandre P; Miller M; Descamps D
J Virol; 2005 Aug; 79(15):9572-8. PubMed ID: 16014919
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Kagan RM; Lee TS; Ross L; Lloyd RM; Lewinski MA; Potts SJ
Antiviral Res; 2007 Sep; 75(3):210-8. PubMed ID: 17442410
[TBL] [Abstract][Full Text] [Related]
11. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
12. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
[TBL] [Abstract][Full Text] [Related]
13. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.
Winston A; Pozniak A; Mandalia S; Gazzard B; Pillay D; Nelson M
AIDS; 2004 Apr; 18(6):949-51. PubMed ID: 15060444
[No Abstract] [Full Text] [Related]
14. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Becker S; Feinberg J
AIDS Clin Care; 2003 Sep; 15(9):81. PubMed ID: 14669727
[TBL] [Abstract][Full Text] [Related]
15. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Kuritzkes DR
J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
17. Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
d'Ettorre G; Mastroianni CM; Massetti AP; Lichtner M; D'Agostino C; Vullo V
AIDS; 2005 May; 19(8):841-2. PubMed ID: 15867503
[No Abstract] [Full Text] [Related]
18. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Balestre E; Dupon M; Capdepont S; Thiébaut R; Boucher S; Fleury H; Dabis F; Masquelier B;
J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
[TBL] [Abstract][Full Text] [Related]
19. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Khanlou H; Yeh V; Guyer B; Farthing C
AIDS Patient Care STDS; 2005 Mar; 19(3):135-40. PubMed ID: 15798380
[TBL] [Abstract][Full Text] [Related]
20. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Margot NA; Waters JM; Miller MD
Antimicrob Agents Chemother; 2006 Dec; 50(12):4087-95. PubMed ID: 16982781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
